Who are Allergen Immunotherapy Extract's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AllerT, AIT Tablet, Staloral TM, PURETHAL Birch, 20.000 AUM/ml, tree 12 SQ-Bet, Novel dose adjustment of Alutard SQ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allergen-immunotherapy-extract.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Allergen Immunotherapy Extract — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allergen Immunotherapy Extract (Allergen Immunotherapy Extract) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology.

phase 3 Allergen immunotherapy Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Allergen Immunotherapy Extract (Allergen Immunotherapy Extract) — Johns Hopkins University. Allergen immunotherapy extract desensitizes the immune system to specific allergens by gradually exposing patients to increasing doses, promoting immune tolerance and reducing allergic responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Allergen Immunotherapy Extract TARGET	Allergen Immunotherapy Extract	Johns Hopkins University	phase 3	Allergen immunotherapy
AllerT	AllerT	Anergis	marketed	Allergen immunotherapy (peptide-based)	Allergen-derived peptide epitopes
AIT Tablet	AIT Tablet	ALK-Abelló A/S	marketed	Allergen immunotherapy
Staloral TM	Staloral TM	National Taiwan University Hospital	marketed	Allergen immunotherapy
PURETHAL Birch, 20.000 AUM/ml	PURETHAL Birch, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Birch pollen allergens (Bet v 1 and related proteins)
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
Novel dose adjustment of Alutard SQ	Novel dose adjustment of Alutard SQ	Beijing Tongren Hospital	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Allergen Immunotherapy Extract — Competitive Intelligence Brief. https://druglandscape.com/ci/allergen-immunotherapy-extract. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing